Clinical trials: Attention
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Attention Deficit Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
- Trial name
- NCT03659929
- Testing
- Amphetamine Sulfate
- Where
- 31 sites in United States
- Volunteers
- 320 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Pharmacokinetics
Effect of Delivery Route on PK of Sufentanil NanoTab
Determine whether the amount of drug absorbed is different if the tablet is placed under the tongue, placed between the cheek and gum, or swallowed.
- Trial name
- NCT01639729
- Testing
- Treatment A: Sufentanil IV, Treatment B: Sufentanil NanoTab Sublingual, Treatment C: Sufentanil NanoTab Buccal
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Talphera, Inc
Dry Eye Disease
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT01743729
- Testing
- Lifitegrast
- Where
- 31 sites in United States
- Volunteers
- 720 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
ADHD
Efficacy and Safety of SPD503 in Combination With Psychostimulants
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal…
- Trial name
- NCT00734578
- Testing
- SPD503-AM, SPD503-PM
- Where
- 61 sites in United States
- Volunteers
- 461 people
- Sponsor
- Shire
Attention-Deficit/Hyperactivity Disorder
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
- Trial name
- NCT06185985
- Testing
- SPN-812
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Investigating the Effect of Vortioxetine in Adult ADHD Patients
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
- Trial name
- NCT02327013
- Testing
- vortioxetine 10 mg tablet, vortioxetine 20 mg tablet
- Where
- 15 sites in United States
- Volunteers
- 227 people
- Sponsor
- H. Lundbeck A/S
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a…
- Trial name
- NCT00419445
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- CoMentis
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
ADHD, Attention Deficit Disorder
Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
This study measures the safety and efficacy of repeated low dose MM120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
- Trial name
- NCT05200936
- Testing
- MM120
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 53 people
- Sponsor
- Definium Therapeutics US, Inc.
Healthy Subjects
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
This study will test the safety, tolerability and blood concentrations of single and multiple oral doses of PF-06751979 in health subjects and healthy elderly subjects.
- Trial name
- NCT02793232
- Testing
- PF-06751979 single dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult…
- Trial name
- NCT00636818
- Testing
- Atomoxetine
- Where
- 11 sites in China, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- Eli Lilly and Company
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Attention Deficit/Hyperactivity Disorder
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
- Trial name
- NCT01338818
- Testing
- Ritalin LA (methylphenidate hydrochloride extended release)
- Where
- 48 sites in United States, Belgium and 4 more
- Volunteers
- 299 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
- Trial name
- NCT01654250
- Testing
- NWP09
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Septic Shock
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
This is a double-blind, placebo-controlled, randomized, multicenter proof of concept and dose-finding phase II study using two doses of ADRECIZUMAB in patients with early septic shock and a bio-ADM plasma concentration at…
- Trial name
- AdrenOSS-2 (NCT03085758)
- Testing
- Adrecizumab
- Where
- 30 sites in Belgium, France and 2 more
- Volunteers
- 301 people
- Sponsor
- Adrenomed AG
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
- Trial name
- NCT00150618
- Testing
- SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg)
- Volunteers
- 324 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire